FIELD: chemistry; biotechnology.
SUBSTANCE: invention relates to biochemistry, in particular to an antibody which specifically binds to claudin 18.2. Also disclosed is a nucleic acid molecule coding said antibody; host cell containing said nucleic acid molecule; conjugate of said antibody; pharmaceutical composition containing said antibody. Disclosed are a method of treating a disease and a method of immunological analysis, in which said antibody is used.
EFFECT: invention provides effective treatment of diseases associated with claudin 18.2.
19 cl, 3 dwg, 16 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY, AND USE THEREOF | 2020 |
|
RU2824390C2 |
ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
Authors
Dates
2024-07-09—Published
2020-03-31—Filed